A 60-year-old patient with atrial fibrillation is assessed as being at intermediate risk for stroke, matching a CHA2DS2-VASc score of 1 in a man or 2 in a woman. They ask whether starting a direct oral anticoagulant is supported by randomized trial evidence compared with no anticoagulation.
What does the evidence in this abstract support for patients with atrial fibrillation at intermediate stroke risk?
